Organ damage in Systemic Lupus Erythematosus patients : A multifactorial phenomenon
Copyright © 2023 Elsevier B.V. All rights reserved..
The prevention of chronic damage, especially in early disease phases, remains an unmet need in the management of Systemic Lupus Erythematous (SLE) patients, despite the application of a so-called treat-to-target strategy. The high proportion of SLE patients developing chronic damage suggests a multifactorial aetiology. Thus, besides disease activity, other factors may contribute to the development of damage. The revision of data published so far underlines that, next to disease activity, it is possible to identify other factors playing a relevant role in damage development and progression. In summary, the presence of antiphospholipid antibodies and drugs used to treat SLE patients, in particular glucocorticoids, is strongly associated with SLE-related damage. Furthermore, recent data suggests the possible role of genetic background in determining the development of specific organ damage, in particular renal and neurological. Nonetheless, demographic factors, such as age, sex and disease duration could exert a role along with the presence of comorbidities. The contribution of different factors in determining damage development suggests the need for new outcomes to assess a comprehensive disease control including not only the assessment of disease activity, but also the evaluation of chronic damage development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 22(2023), 8 vom: 09. Aug., Seite 103374 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ceccarelli, Fulvia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aetiology |
|---|
| Anmerkungen: |
Date Completed 28.07.2023 Date Revised 28.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2023.103374 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358030161 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358030161 | ||
| 003 | DE-627 | ||
| 005 | 20231226073855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2023.103374 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM358030161 | ||
| 035 | |a (NLM)37301273 | ||
| 035 | |a (PII)S1568-9972(23)00108-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ceccarelli, Fulvia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Organ damage in Systemic Lupus Erythematosus patients |b A multifactorial phenomenon |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2023 | ||
| 500 | |a Date Revised 28.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a The prevention of chronic damage, especially in early disease phases, remains an unmet need in the management of Systemic Lupus Erythematous (SLE) patients, despite the application of a so-called treat-to-target strategy. The high proportion of SLE patients developing chronic damage suggests a multifactorial aetiology. Thus, besides disease activity, other factors may contribute to the development of damage. The revision of data published so far underlines that, next to disease activity, it is possible to identify other factors playing a relevant role in damage development and progression. In summary, the presence of antiphospholipid antibodies and drugs used to treat SLE patients, in particular glucocorticoids, is strongly associated with SLE-related damage. Furthermore, recent data suggests the possible role of genetic background in determining the development of specific organ damage, in particular renal and neurological. Nonetheless, demographic factors, such as age, sex and disease duration could exert a role along with the presence of comorbidities. The contribution of different factors in determining damage development suggests the need for new outcomes to assess a comprehensive disease control including not only the assessment of disease activity, but also the evaluation of chronic damage development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aetiology | |
| 650 | 4 | |a Chronic damage | |
| 650 | 4 | |a Disease activity | |
| 650 | 4 | |a Systemic Lupus Erythematosus | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Perricone, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Natalucci, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Picciariello, Licia |e verfasserin |4 aut | |
| 700 | 1 | |a Olivieri, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Cafaro, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoloni, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Roberto, Gerli |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 22(2023), 8 vom: 09. Aug., Seite 103374 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:8 |g day:09 |g month:08 |g pages:103374 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2023.103374 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 8 |b 09 |c 08 |h 103374 | ||